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Objectives: Our objectives were to determine the feasibility, etficacy, and 
safety of in vivo and ex vivo liposome-mediated gene transfer to lung 
isografts. Methods: Fischer rats were divided into three main groups: (1) 
Nontransplant setting: Liposome-chloramphenicol acetyl transferase cDNA 
was intravenously injected, and lungs were harvested at different time 
points: 2, 6, 12, and 24 hours; 2, 5, 8, and 21 days (n = 3). Chloramphenicol 
acetyl transferase activity was determined in lungs, hearts, livers, and 
kidneys. The distribution and type of transfected cells were evaluated by in 
situ hybridization. Lung toxicity was assessed by arterial oxygen tension, 
histology, and tumor necrosis factor-ol evels. (2) In vivo graft transfection: 
Left lungs were transplanted 6 hours, 4 hours, and 15 minutes after 
intravenous injection and were assessed for chloramphenicol acetyl trans- 
ferase activity and arterial oxygen tension on postoperative day 2. (3) Ex 
vivo graft transfection: Grafts were infused ex vivo with either 660 ~g (n = 
3) or 330/~g (n = 3) of DNA complexed to liposomes and stored at 10 ° C for 
4 hours. Chloramphenicol acetyl transferase activity was assessed 44 hours 
after transplantation. Results: Transgene xpression was detected in endo- 
thelial cells, macrophages, and interstitial cells. Chloramphenicol acetyl 
transferase activity was present as early as 2 hours, increased significantly 
between 6 hours and 8 days, and then decreased to minimal levels by 21 
days. Chloramphenicol acetyl transferase activity was greatest in donor 
lungs and hearts and minimal in livers and kidneys. Arterial oxygen tension 
was normal in treated animals. Inflammation was minimal, and tumor 
necrosis factor-~ levels increased only sevenfold in treated animals. 
Conclusion: In vivo and ex vivo liposome-mediated gene transfer to lung 
isografts allows significant ransgene xpression with minimal effects on 
graft function. (J Thorac Cardiovasc Surg 1997;114:783-92) 
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L ung transplantation has become an effective ther- apeutic option for the treatment of a variety of 
end-stage pulmonary disorders. At present, isch- 
emia-reperfusion i jury and infection are the most 
common causes of early morbidity and mortality, 
whereas chronic rejection accounts for the majority 
of late mortality. Modifications of donated organs 
before implantation, by means of gene therapy 
techniques, may improve graft function and overall 
survival. 
Several prerequisites must be met for gene ther- 
apy to be clinically useful in the setting of organ 
transplantation: (1) Efficient and reproducible 
transgene xpression in the graft should be present; 
(2) graft toxicity should be avoided to minimize 
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further worsening of the transient functional impair- 
ment that is inherent o the transplant procedure 
itself; (3) transgene xpression should be homoge- 
neously distributed throughout the graft parenchy- 
ma; (4) organ specificity should be achieved because 
multiple cadaveric organ recovery is routine; and (5) 
for the prevention of ischemia-reperfusion injury, 
transgene expression should be present before 
reperfusion of the graft in the recipient. Although 
transient expression is regarded as one of the draw- 
backs of current gene delivery systems, this actually 
is desirable in the treatment of acute, self-limited 
conditions uch as ischemia-reperfusion njury. 
A variety of delivery systems, both viral and 
nonviral, have been used. 1 Retroviruses require 
active cell division to integrate the transferred DNA 
into the host genome and initiate transcription. 
Because this insertion occurs randomly in the ge- 
nome, the potential for cancerous mutagenesis ex- 
ists. 2 Further, retroviral vectors are not suitable for 
lung or heart tissues, because cell turnover is slow in 
these organs. 
Adenoviruses, rendered replication deficient by 
deletion of the E1 region, can be produced in high 
titers and are capable of transfecting a wide variety 
of dividing and resting cells with good efficiency) 
They do not integrate into the host genome and 
therefore have little chance to activate a dormant 
oncogene or interrupt a tumor suppressor gene. 4
The major limitation of current adenoviral vectors is 
the resultant host inflammatory and immune re- 
sponse, leading to the destruction of transduced 
cells, s-7 Another limitation is the potential for the 
production of replication-competent viral strains 
through omologous recombination, which can have 
serious consequences in the setting of immunosup- 
pression and transplantation. 
Because of limitations with viral vectors, attempts 
are underway to develop efficient nonviral alternative 
delivery systems. Cationic liposomes consist of a pos- 
itively charged lipid mixed with a neutral lipid such as 
L-dioleoyl phosphatidyl-ethanolamine (DOPE) that 
forms complexes with plasmid DNA and facilitates its 
transport into the cell. Such liposomes can introduce 
DNA into replicating and nonreplicating cells with 
little toxicity. 7 Because they do not incite a significant 
host immune response, repeat administration is possi- 
ble. The administered plasmid DNA remains extra- 
chromosomal nd results in transient gene expression, 
similar to adenoviral vectors,  There are also no ap- 
parent restrictions on the size of the transferred genes. 
The aim of this study was to achieve transgene 
expression in transplanted lung grafts after in vivo 
and ex vivo administration of cationic lipids com- 
plexed to a reporter gene. The time course of gene 
expression, distribution, and type of transfected cells 
and the effects of the transplant procedure on 
transgene xpression were examined. 
Materials and methods 
Plasmid expression vector. The plasmid pCF1-CAT 
(Genzyme Corporation, Framingham, Mass.) consists of 
the human cytomegalovirus immediate arly gene pro- 
moter/enhancer, a hybrid intron, the chloramphenicol 
acetyl transferase (CAT) cDNA, the bovine growth hor- 
mone polyadenylation signal sequence, and the kanamy- 
cin resistance gene, as previously described. 9 
Preparation of cationic lipid/DNA complexes. Lipid 67 
(Genzyme) is an amphophile consisting of a hydrophobic 
cholesterol lipid anchor linked to a spermine head group 
in a T-shaped configuration. 9 Lipid 67 was mixed with 
DOPE in a 1:2 molar ratio as previously described? 
Before use, the dried lipid films were hydrated with sterile 
water, mixed with an equal volume of plasmid DNA, and 
allowed to sit at room temperature for a minimum of 15 
minutes. Final concentrations were 1 mmol/L for the 
cationic lipid mixture and 4 mmol/L for the plasmid DNA. 
Immediately before injection in animals, the resulting 
complex was diluted with an equal volume of normal 
saline solution. 
Animals. Inbred male Fischer ats weighing 270 to 300 
gm (Charles River Laboratories, Wilmington, Mass.) were 
used in all experiments. All animals received humane care 
in compliance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Labo- 
ratory Animal Resources and published by the National 
Institutes of Health (NIH Publication No. 85-23, revised 
1985). 
Nontransplant setting: In vivo transfection of normal 
lungs. The first group of experiments aimed to determine 
(1) the feasibility of in vivo gene transfer to donor lungs by 
way of the intravenous route, (2) the rapidity of transgene 
expression, (3) the duration of transgene xpression, (4) 
the degree of vector-related lung toxicity, and (5) the 
extent of extrapulmonary t ansgene expression. 
Rats were premedicated with inhaled halothane and a 
subcutaneous injection of ketamine chloride (25 mg/kg) 
and atropine sulfate (0.25 mg/kg). After endotracheal 
intubation with a 14-gauge catheter, animals' lungs were 
mechanically ventilated with a small-animal Harvard ven- 
tilator (Harvard Apparatus Co., Inc., South Natick, Mass.) 
(tidal volume 3 ml, respiratory rate 60 breaths/rain) with 
0.5% halothane and 99.5% oxygen. A small incision was 
made in the left lower part of the neck and the left 
external jugular vein was mobilized. The liposome-CAT 
complex (1320 /xg of DNA) was injected intravenously 
over a period of 3 to 4 minutes. The incision was then 
closed and the animals allowed to recover from anesthe- 
sia. 
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Animals were divided into eight groups (n = 3) and 
killed at various times after intravenous injection: 2, 6, 12, 
and 24 hours and 2, 5, 8, and 21 days. In addition, four 
animals were killed at 6 months. Before they were put to 
death, arterial oxygenation was measured with both lungs 
ventilated at an inspired oxygen fraction of 100% for a 
minimum of 5 minutes. At the time of harvest, both lungs 
were flushed with normal saline solution via the main 
pulmonary artery. The right lung, heart, liver, and kidneys 
were harvested, snap-frozen i  liquid nitrogen, and stored 
at -80°C for assessment of CAT activity and tumor 
necrosis factor-a (TNF-c 0 levels. The left lung was fixed 
in 10% buffered formalin for histologic examination. 
Transplant setting: In vivo graft transfection. The sec- 
ond group of experiments studied the influence of the 
transplant procedure on transgene expression. Donor 
animals were treated with an intravenous injection of the 
liposome-CAT complex as described earlier and were 
divided into six groups. In groups I, II, and III, the left 
lungs were harvested 6 hours, 4 hours, and 15 minutes 
after intravenous administration, respectively, and then 
transplanted. Recipient animals were killed on postoper- 
ative day 2. After a normal saline solution flush, the 
harvested transplanted lung grafts were snap-frozen in 
liquid nitrogen and stored at -80 ° C for later assessment 
of CAT activity. In groups IV, V, and VI, lungs were not 
transplanted. These groups served as controls and con- 
sisted of transfected left lungs that were harvested 6 hours 
(group IV), 4 hours (group V), and 48 hours (group VI) 
after intravenous administration of liposome-DNA com- 
plexes. 
Transplant setting: Ex vivo graft transfection. The 
third group of experiments studied the feasibility of ex 
vivo liposome-mediated gene transfer to lung isografts. 
Left lungs were harvested and divided into two groups. In 
group I (n = 3), 330 /xg of CAT cDNA:lipid 67:DOPE 
(0.25 ml of the original preparation) was diluted in 10 ml 
of 0.9% saline solution and infused into the left lung via 
the left pulmonary vein over a 7- to 10-minute period. 
Grafts were stored at 10°C for 4 hours and then im- 
planted. In group II (n = 3), grafts underwent the same 
procedure but received 660 /~g of CAT cDNA:lipid 67: 
DOPE (0.5 ml of the original preparation). 
Rat lung transplantation. A rat orthotopic left lung 
transplant model (Fischer to Fischer) was developed with 
the use of a modification of the cuff technique, s°as described 
elsewhere. 11In brief, donors were anesthetized, intubated, 
and heparinized and then underwent a median sternotomy- 
laparotomy. The abdominal aorta, inferior vena cava, and 
the left atrial appendage were incised, and the lungs were 
flushed through the main pulmonary artery with cold low- 
potassium dextrart/l% glucose solution. After the heart-lung 
block was excised with the lungs inflated at end-tidal volume, 
the left lung was dissected away. In the case of ex vivo 
transfection, a second flush of normal saline solution con- 
taining the CAT gene was performed at this point, as 
described earlier. After this, 14-gauge Teflon cuffs were 
inserted into the left pulmonary artery and vein. The left 
lung was then stored in low-potassium dextran/glucose solu- 
tion at 4 ° C (or at 10 ° C in the case of ex vivo transfection) 
until implantation. 
Recipient rats were anesthetized, intubated, and sub- 
jected to a left thoracotomy. The left main bronchus was 
ligated distally and the pulmonary vessels were cross- 
clamped proximally. The donor lung vessels were then 
anastomosed to the corresponding recipient vessels by 
means of the cuff technique. The bronchial anastomosis 
was performed with a running 9-0 Prolene suture (Ethi- 
con, Inc., Somerville, N.J.). Ventilation and perfusion to 
the graft were restored and a chest tube was inserted 
temporarily and then removed after the return of sponta- 
neous respirations. 
CAT activity assay. Transgene xpression was detected 
by a CAT activity assay as described elsewhere. 12In brief, 
after tissue homogenization a d dilution in Tris-ethylenedi- 
amine tetraacetic acid, three consecutive freeze/thaw cy- 
cles were performed. After incubation at 65 ° C, samples 
were centrifuged at 10,000 rpm, and then the supernatant 
was recovered and a quantitative spectrophotometric pro- 
tein analysis was performed. Protein extract, 300 Izg, was 
incubated overnight at 37 ° C with 40 txl of acetyl coenzyme 
A (5 mg/ml) and 8 Izl of 14C-chloramphenicol. Ethyl 
acetate was added, the samples were placed in a vortex, 
centrifuged at 14,000 rpm, and the organic supernatant 
was recovered. This was nitrogen-dried and then resus- 
pended in ethyl acetate. Thin-layer chromatography was 
followed by overnight autoradiography. In the presence of 
functional CAT enzyme, both monoacetylated and di- 
acetylated forms of chloramphenicol are produced, which 
are distinct from the nonacetylated chloramphenicol. 
In sitn hybridization and immunohistochemistry. In situ 
hybridization was performed with sense and antisense 
35S-radiolabeled cRNA for CAT as previously de- 
scribedJ 3
Immunohistochemistry with the ED1 antibody, which is 
specific to rat macrophages, was performed as previously 
described. 14A double-label study (immunohistochemis- 
try-in situ hybridization) was performed to confirm that 
macrophages xpressed the CAT gene. 
Evaluation of puhnonary toxicity. The resulting host 
inflammatory esponse was evaluated by measurement of
TNF-c~ levels in lung tissue from treated and untreated 
animals, using an enzyme-linked immunosorbent assay kit 
(Intertest, Genzyme). 
The inflammatory infiltrate was also evaluated by ex- 
amining thin sections of lung tissue stained with hematox- 
ylin and eosin. In addition, macrophages (EDl-positive 
cells) were counted both in intravenously transfected 
lungs (n = 3) and in normal controls (n = 3). Ten 
high-power fields (100×) for each sample were analyzed 
and averaged. 
Lung gas exchange was determined by measurement of 
arterial oxygen tension (Pao2). In brief, the right pulmo- 
nary artery and right main-stem bronchus of transplant 
recipients were clamped and the left lung was ventilated 
for 5 minutes at a 100% inspired oxygen fraction, a tidal 
volume of 2 ml, and a respiratory rate of 80 breaths/min. 
An arterial blood sample was obtained from the abdom- 
inal aorta. In the nontransplant setting, arterial oxygen- 
ation was determined while both lungs were ventilated. 
Statistical analysis. Data were compared by one-way 
analysis of variance or unpaired t test, as applicable, 
by means of the software SYSTAT 6.0 for Windows 
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Fig. 1. Lung CAT activity at different times after intravenous administration. Each column corresponds to 
one animal. The bottom row represents nonacetylated chloramphenicol. The middle and top rows represent 
monoacetylated and diacetylated chloramphenicol, respectively. A, CAT activity is maximal as early as 6 
hours after intravenous infusion. One animal in the 12-hour group lost the intravenous injection because 
of a technical failure. B, CAT activity is high for at least 8 days. 
(SYSTAT Inc., Evanston, Ill.). Data were expressed as 
mean +_ standard error, with ap value < 0.05 considered 
statistically significant. 
Results 
All animals survived the operative procedures. 
Transgene expression was present in all animals 
treated with the lipid 67:DOPE:pCF1-CAT com- 
plex, except in one animal of the 12-hour group in 
which the injection was missed because of a techni- 
cal failure. 
Onset and duration of transgene expression. In 
the nontransplant setting, transgene xpression was 
detectable at low levels as early as 2 hours after 
intravenous administration. Higher expression was 
detected at 6 hours and continued until 8 days. By 
21 days, transgene xpression declined to minimal 
levels (Fig. 1, A and B). 
Distribution of transfected cells. In situ hybrid- 
ization revealed homogeneous and widespread is- 
tribution of transgene xpression throughout he 
lung parenchyma. The majority of transfected cells 
were in the pulmonary interstitium (Fig. 2). Cells 
lining the lumen of the larger pulmonary vessels, 
presumably endothelial cells based on their location, 
also expressed CAT mRNA (Fig. 2). Macrophages 
also displayed CAT expression, which was con- 
firmed by double-label studies (immunohistochem- 
istry-in situ hybridization). Transgene expression 
was not observed in airway epithelial cells lining 
bronchi and bronchioles. 
Pulmonary toxicity of lipid 67:DOPE:pCF1-CAT. 
In the nontransplant setting, hematoxylin-eosin tain- 
ing revealed only a minimal inflammatory infiltrate 
present in the lungs of treated animals. An average of 
4.3 + 0.71 macrophages per high-power field was 
noted in control nontransfected lungs compared with 
9.1 ___ 1.18 macrophages per high-power field in trans- 
fected lungs harvested 48 hours after intravenous 
transfection (p = 0.04, unpaired t test). 
Arterial oxygenation showed no differences be- 
tween transfected and nontransfected animals as 
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Distribution of CAT Gene Expression 
A B C 
Fig. 2. In situ hybridization performed with an 35S-radiolabeled CAT antisense cRNA probe. A, CAT 
expression occurred widely throughout the pulmonary interstitium, 48 hours after intravenous administra- 
tion. B and C, CAT expression was also detected incells lining the lumen of pulmonary vessels, presumably 
endothelial cells. 
demonstrated byPao2s obtained 2days, 21 days, and 
6 months after injection and from nontransfected 
normal controls (p = 0.08, one-way analysis of 
variance, Table I). 
TNF-a, a proinflammatory cytokine, increased 
sevenfold in transfected nontransplanted lungs com- 
pared with nontransfected normal ungs (74 _+ 24 vs 
10.7 _+ 2, respectively, n = 3 per group). 
Extrapulmonary transgene expression. CAT ac- 
tivity was measured in several donor organs in- 
cluding the heart, liver, and kidneys in the setting 
of intravenous administration followed by organ 
harvest without transplantation. Heart tissue 
showed levels of CAT activity comparable with 
that in the lungs (Fig. 3). CAT gene expression 
was high in samples obtained separately from the 
free walls of the right and left ventricles. CAT 
activity was minimal in livers and negligible in 
kidneys (Fig. 3). 
In vivo graft transfection. CAT activity in lung 
grafts transfected in vivo for 4 and 6 hours, trans- 
planted, and assessed on postoperative day 2 was 
similar to CAT activity in nontransplanted lungs 
transfected in vivo for 48 hours (Fig. 4). Transgene 
expression was minimal in lungs transfected in vivo 
only 15 minutes before harvest, transplanted, and 
assessed on postoperative day 2. 
Table I. Arterial oxygenation i  transfected animals 
versus nontransfected normal controls 
Time of assessment 
following liposome-DNA 
intravenous administration Pao 2 (ram Hg) 
2 days (n = 10) 545 _+ 15.7 
21 days (n = 4) 468.1 ± 36.3 
6 months  (n = 4) 572.8 _+ 36.1 
Normal  controls (n = 5) 523.5 ± 18.4 
p Value = 0.08, one-way analysis of variance. 
There were no differences (p = 0.99, one-way 
analysis of variance) in arterial oxygenation at 48 
hours in any of these groups (Pao 2 = 523.5 _+ 18.4 
mm Hg, 521.1 _+ 40.8 mm Hg, 529.3 _+ 11 mm Hg, 
and 537.2 _+ 71.2 mm Hg, obtained from nontrans- 
fected normal controls and animals transfected 6 
hours, 4 hours, and 15 minutes before transplanta- 
tion, respectively). 
Ex vivo graft transfeetion. In this setting, all lung 
grafts in groups I and II showed transgene xpres- 
sion (Fig. 5). There was no impairment of graft 
function when the lipid-DNA dose was increased to 
660 /xg of DNA:lipid 67:DOPE (0.5 ml of the 
original solution), as demonstrated bythe Pao 2 data 
(387.9 _+ 6.8 mm Hg and 374.7 +_ 24.5 mm Hg for 
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Lung Liver Heart Kidney 
Fig. 3. CAT expression i lungs, livers, hearts, and kidneys 48 hours after intravenous administration (  = 
3). Minimal CAT activity is present in livers and kidneys when compared with the CAT activity in lungs and 
hearts. 
normal controls and transfected animals, respectively, 
p = 0.6, unpaired t test). However, dose-dependent 
toxicity was observed in lungs transfected with 660/xg 
of DNA:lipid 67:DOPE (0.5 ml) and stored at 23 ° C, 
then transplanted. The grafts in this setting demon- 
strated extensive hemorrhage and edema. This was not 
observed innontransfected lungs preserved for 4 hours 
at 23 ° C and transplanted or lungs transfected ex vivo 
with the use of the same conditions but with 330/xg of 
DNA and 0.25/xmol of liposome. 
Discussion 
Viruses are considered the most efficient gene 
delivery systems. They have developed efficient 
mechanisms for cellular attachment, penetration, 
and avoidance of intracellular lysosomal degrada- 
tion) Despite this, we 15 and others 16' 17 have ob- 
served an unpredictable, nonhomogeneous, patchy 
pattern of transgene xpression with low efficiency, 
when a first-generation adenovirus serotype 5 vector 
was used to introduce xogenous DNA into the pul- 
monary microvasculature, either in vivo or ex rive. 
Liposomes, on the other hand, are regarded as 
less efficient delivery systems, is It has been demon- 
strated in vitro that large amounts of liposome- 
cDNA complexes that enter the cell are trapped in 
endosomes, precluding the cDNA from reaching the 
nucleus and initiating transcription, t8 In addition, 
activation of the complement system by cationic 
lipids, depending on the chemistry of the individual 
compounds used, has been reported.19 Opsonization 
of DNA complexes by complement proteins can 
facilitate phagocytosis by the reticuloendothelial 
system, resulting in rapid clearance of these com- 
plexes from the bloodstream, thereby worsening the 
efficiency of intravenous administration. 19 
Despite these impediments o efficient ransgene 
expression, we observed transgene xpression in all 
treated animals in which we used a liposomal vec- 
tor (lipid 67:DOPE) and a reporter gene (CAT), 
both in transplanted and in nontransplanted lungs. 
Transfected cells were homogeneously distributed 
throughout the lung parenchyma, s confirmed by in 
situ hybridization. CAT mRNA signal was localized 
mainly in the pulmonary interstitium, making it 
difficult to determine whether these were endothe- 
lial, macrophage, or interstitial cells. However, ED1 
immunohistochemistry-in situhybridization studies 
demonstrated CAT expression in macrophages. In
addition, cells lining the lumen of larger pulmo- 
nary vessels, likely endothelial cells, were also 
transfected. Inasmuch as the donor endothelium 
is the first structure to have contact with recipient 
inflammatory cells, gene therapy targeted to do- 
nor endothelial cells is especially attractive and 
could address two important problems in organ 
transplantation: ischemia-reperfusion injury and 
rejection. 
Several investigators 2°-24 have observed a signifi- 
cant inflammatory response when viral vectors were 
used. Vector modifications 4' 5, 23 and administration 
of immunosuppressive drugs 23' 24 have partially cir- 
cumvented the immune and inflammatory responses 
raised by these systems. Nevertheless, viral protein 
expression still occurs, 5resulting in a decrease in the 
duration of transgene xpression. Because of the 
humeral and cellular host immune response, repeat 
administration is not efficient, since transduced cells 
express viral proteins and are promptly destroyed by 
the host immune system. 21 
Using a liposomal vector, we observed a minimal 
inflammatory response in transfected lungs, consist- 
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Fig. 4. CAT activity measured in lung isografts. A, Lungs transfected in vivo for 48 hours, serving as 
controls for B. B, Lung isografts transfected in vivo for 4 hours followed by transplantation a d assessed 
on postoperative day 2. C, Lung isografts transfected in vivo for 6 hours, transplanted, and then assessed 
on postoperative day 2. D, Lungs transfected in vivo for 48 hours and assessed for CAT activity. Th.is group 
was used as a control for group C. CAT activity was not significantly different between transplanted and 
control ungs. 
ing essentially of a mononuclear infiltrate. Although 
TNF-~ levels in transfected lungs increased seven- 
fold compared with levels in nontreated normal 
lungs, arterial oxygenation showed no statistical 
differences between transfected and normal ani- 
mals, in either the nontransplant or transplant set- 
tings. In the nontransplant setting, a decrease in 
arterial oxygenation was observed at 21 days, but the 
decrease was not statistically significant, possibly 
because of the small number of animals in this group 
(n = 4). This demonstrates that there was no 
significant functional impairment as a result of the 
transfection procedure when liposomal vectors were 
used. It is also consistent with studies in healthy 
human volunteers, revealing no acute adverse ef- 
fects on pulmonary function when a liposome ad- 
ministered by aerosol inhalation was used. 2s In our 
study, the intravenous administration of liposome- 
DNA complexes did not result in chronic adverse 
functional effects in lungs, as demonstrated by gas 
exchange determined 6 months after intravenous 
transfection. This is of paramount importance in the 
transplant setting, where the delivery system must 
not be another source of injury to the transplanted 
organ. 
The route of administration seems to influence 
the magnitude of the inflammatory response. We 
observed significantly higher levels of TNF-o~ when 
similar amounts of lipid 67:DOPE:pCF1-CAT com- 
plexes were administered intratracheally than when 
given intravenously (300- to 400-fold increase versus 
sevenfold increase, respectively, compared with 
nontransfected lungs; data not shown). One expla- 
nation may be that airway defense mechanisms are 
somehow more reactive as the airways are exposed 
directly to environmental insults on a regular basis. 
This could lead to a prompt and more intense 
inflammatory response to external agents intro- 
duced by this route. 
Liposomal systemic toxicity has not been found in 
previous studies. 26' 27 No deleterious effects have 
been shown on hearts, kidneys, and livers according 
to electrocardiographic, histologic, serum enzyme, 
and blood chemistry studies. Studies with functional 
genes might clarify whether transgene xpression in 
other organs would pose a problem in the setting of 
multiple cadaveric organ retrieval. 
Transient expression is considered one of the 
drawbacks of current adenoviral and liposomal vec- 
tors. In this study, CAT activity was detected for a 
minimum of 8 days after intravenous administration, 
decreasing significantly by 21 days. Possible expla- 
nations for this include (1) loss of plasmid from 
transfected cells, (2) down-regulation of the cyto- 
megalovirus promoter, and (3) loss of transfected 
cells owing to necrosis or apoptosis. 9 However, 
inasmuch as ischemia-reperfusion injury is a self- 
limiting phenomenon, transient expression may be 
sufficient o ameliorate such injury. Furthermore, 
liposome-DNA complexes have been repeatedly ad- 
ministered without inducing an inflammatory re- 
sponse. Canonico and associates 28 have demon- 
strated that weekly intravenous or aerosol delivery 
of liposome:oq-antitrypsin cDNA complexes in rab- 
bits resulted in sustained transgene xpression and 
did not affect lung histology, mechanics, and oxygen- 
ation. Lee and coworkers 9 have administered lipid 
67:DOPE:CAT to mice previously treated with lipid 
67:DOPE:cystic fibrosis transmembrane conduc- 
tance regulator cDNA. The level of CAT activity 
was equivalent to that detected in mice that received 
a single administration of lipid 67:DOPE:CAT, 
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Fig. 5. CAT activity was present in all grafts transfected ex vivo at 10 ° C with either 660/xg or 330/xg of 
DNA. A, Lung grafts transfected with 660/zg of DNA and 0.5 txmol of lipid 67:DOPE diluted in 10 ml of 
normal saline solution (n = 3). B, Lung grafts transfected with 330/xg of DNA and 0.25/xlnol of lipid 67 
diluted in 10 ml of normal saline solution (n = 3). 
demonstrating no immune response against the 
liposomal vector. 
If the goal is a modification of ischemia-reperfu- 
sion injury, then transgene xpression at the time of 
implantation is ideal. We have developed a strategy 
to transfect the grafts in vivo, before harvest, so that 
transgene expression would be present at the time of 
reperfusion. Our results demonstrate hat gene ex- 
pression, albeit low, was present as early as 2 hours 
after intravenous injection and increased signifi- 
cantly 4 to 6 hours after intravenous injection in the 
donor. In addition, we observed that the transplant 
procedure itself did not affect subsequent transgene 
expression. 
Target specificity is also desirable in the trans- 
plant setting. In our study, donor intravenous treat- 
ment with liposome-CAT complexes before harvest 
led to transgene xpression i  donor hearts at levels 
comparable with those detected in lungs. Analysis of 
CAT activity in isolated right and left ventricles 
showed equivalent transgene xpression, indicating 
that the lipid-CAT complex can cross the pulmonary 
microvasculature. On the other hand, CAT activity 
was minimal in livers and negligible in kidneys. It is 
not clear whether this transfection pattern is due to 
tissue affinity or to a first-passage phenomenon, 
inasmuch as hearts and lungs are the first organs to 
receive the liposome-DNA complex when the jugu- 
lar route is used. A similar pattern of transgene 
expression has also been reported by other investi- 
gators using liposomes injected through the tail vein 
of mice. 26' 29 In another study conducted in rab- 
bits, 28 the intravenous administration of a cationic 
lipid complexed to the human al-antitrypsin cDNA 
resulted in transgene xpression predominantly in
lungs and livers, but not in kidneys. Surprisingly, in 
the same study transgene xpression was also de- 
tected in livers when the liposome-DNA complexes 
were administered through the airways, demonstrat- 
ing that this route of administration does not assure 
gene expression exclusively in lungs. 
Although the in vivo approach offers the advan- 
tage of transgene xpression at the time of implan- 
tation, it lacks target organ specificity. The ex vivo 
approach may address this issue. Recently, the 
feasibility of efficient ex vivo cationic lipid-mediated 
gene transfer to rabbit heart allografts at 4°C has 
been demonstrated. 3° In the lung transplant setting, 
the ex vivo approach offers the opportunity to 
specifically target he lungs. Our results demonstrate 
that reproducible transgene expression can be 
achieved with this approach, without significant 
injury to the graft. All lung isografts treated ex vivo 
showed transgene xpression. 
In summary, our data demonstrate that in vivo 
and ex vivo cationic lipid-mediated gene transfer to 
lung isografts allows reproducible and widespread 
transgene xpression, without acute or chronic im- 
pairment of graft function. Whether these levels of 
transgene xpression are sufficient o yield a func- 
tional effect requires further studies with functional 
genes. In addition, the ischemic insult imposed on 
the grafts by the transplant procedure did not alter 
transgene xpression. Thus liposomal vectors are 
relatively safe gene delivery systems and may prove 
useful in lung transplantation. 
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Discussion 
Dr. Duane Davis (Durham, N.C.). I have a few ques- 
tions regarding the actual percent of the cells that were 
transfected. You presented global assays of activity and 
some photo monographs. Do you have any idea of what 
percentage of cells were transfected? 
Second, what kind of dose response did you obtain? I 
saw little difference between 330 and 660/xg of DNA. Was 
expression actually better with higher doses? What is the 
effect of temperature or pressure or any of the other 
things that we would usually try to alter to enhance 
delivery? 
Dr. Boasquevisque. We did not count the number of 
cells that were transfected. This information would be 
more interesting to have when we use functional genes, so 
that the number of transfected cells could be correlated 
with the presence or absence of a functional effect. 
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We cannot say whether there is a difference in the 
amount of transgene xpression when we use 330 txg 
compared with 660 p.g. Even in this assay, if more than 
50% of the substrate is converted by the enzyme in the 
extract, it is not possible to detect any difference between 
the groups. 
Regarding the influence of temperature on transgene 
efficiency, in some animals transfection was done at 
room temperature, and the expression was really much 
higher than at cold temperatures. In this study the 
transfection was done at 10 °C, but we also have 
performed some experiments in which we transfected 
the lungs at 4 ° C, and we noted a clear difference. We 
did not check the effect of pressure. All these perfu- 
sions in the ex vivo setting were done at 20 cm HaO. 
Dr. Larry R. Kaiser (Philadelphia, Pa.). You showed a 
couple of in situ hybridizations. Do you have any idea 
about the distribution in your in situ cases? Did you 
retrieve biopsy specimens of various areas of the lung, or 
did you just look at a random area to get some idea, at 
least qualitatively, of the percentage or the numbers of 
cells that are expressing your CAT gene? 
Dr. Boasquevisque. We analyzed the whole lung, but we 
did not count the percentage of cells. 
